COMPASS Pathways
Business Services · United Kingdom · 51-200 Employees
View Company Info for Free
Overview
Headquarters
33 Broadwick St, London, Greater London,...Phone Number
+44 7166766461Website
www.compasspathways.comRevenue
$132 MillionStock Symbol
CMPSIndustry
ZI Rank: 2
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
2
1
4
1
2
About COMPASS Pathways
COMPASS Pathways plc (Nasdaq: CMPS) is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. Our focus is on improving the lives of those who are suffering with mental health challenges and who are not helped by current treatments. We are pioneering the development of a new model of psilocybin therapy, in which our proprietary formulation of synthetic psilocybin, COMP360, is administered in conjunction with psychological support.Explore more
COMPASS Pathways Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is COMPASS Pathways your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when COMPASS Pathways launches new products
Click to see if COMPASS Pathways had a recent Job posting/layoffs
Check if COMPASS Pathways has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at COMPASS Pathways
COMPASS Pathways, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on COMPASS Pathways recently announced quarterly report
Funding: Get notified immidiatlly once COMPASS Pathways has new funding data
Check out if COMPASS Pathways is spiking on competitors!
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Compare Similar Companies to COMPASS Pathways
Compare insights from companies similar to COMPASS Pathways, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
COMPASS Pathways is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
COMPASS Pathways is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about COMPASS Pathways.
COMPASS Pathways financials insights
Gather financial insights about COMPASS Pathways, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2018
Series A
$35.5M
2020
Series B
$80M
Stock Offering
$128M
2023
Debt
$50M
Other Financing Round
$285M
COMPASS Pathways Tech Stack
A closer look at the technologies used by COMPASS Pathways
Most Recent Scoops
Open Position
Open Position
Open Position
Open Position
Open Position
COMPASS Pathways News & Media
Compass Pathways Elects Kathleen Tregoning to Board of Directors - Times Argus
LONDON & NEW YORK--(BUSINESS WIRE)--May 28, 2026--COMPASS Pathways plc (CMPS) Q1 2026 Earnings Call Transcript
COMPASS Pathways plc (CMPS) Q1 2026 Earnings Call May 13, 2026 8:00 AM EDTCompany ParticipantsStephen Schultz - Senior Vice President of Investor...FDA Grants Rolling Review and CNPV Designation to Compass Pathways (CMPS) for TRD Treatment
Compass Pathways (NASDAQ:CMPS) is one of the small cap stocks with the highest upside potential. On April 24, Compass Pathways announced that the US FDA granted a rolling review for its NDA and selected COMP360 for the Commissioner’s National Priority Voucher/CNPV program. COMP360 is a proprietary synthetic psilocybin formulation designed for patients with treatment-resistant depression/TRD. […]Trump Sends Compass Pathways Stock Soaring as He Backs Psychedelics. Should You Buy CMPS Here?
Compass Pathways stock rallies as Trump’s new executive order aims at accelerating approval and research of psychedelic medicines. But is it too late to invest in CMPS shares already?
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding COMPASS Pathways
Sign Up For FreeTo access detailed company insights
COMPASS Pathways plc (Nasdaq: CMPS) is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. Our focus is on improving the lives of those who are suffering with mental health challenges and who are not helped by current treatments. We are pioneering the development of a new model of psi... Read More
